CHAF1B — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

	Compound	Confidence	Supporting neighbours

Clinical trials — most relevant to CHAF1B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room	PHASE2/PHASE3	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	PHASE2	COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors	PHASE1	COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers	PHASE1	COMPLETED
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Macrophage Inhibitory Factor and High-Mobility Group-1 Protein in Children Undergoing Cardiopulmonary Bypass	nan	COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia	nan	COMPLETED
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
Efficacy of Cognitive Rehabilitation Using Virtual Reality and Computer-based Cognitive Stimulation on Cognitive Impairment Associated to Movement Disorders	nan	COMPLETED
Inhibition of Che-1/AATF as a New Tool in Multiple Myeloma Treatment	nan	UNKNOWN
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
Research on the Early and Prognosis Diagnosis of Vascular Dementia	nan	RECRUITING
Clinical and Genomic Registry of MDS in Asia	nan	UNKNOWN
Gene Expression of Endocannabinoid System in Episodic and Chronic Migraine Patients	nan	COMPLETED
The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity	nan	COMPLETED
Effect of Exercise on the Human Skeletal Muscle Phosphoproteome	nan	COMPLETED
Genetic Characterization of Parkinson's Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CHAF1B binder may also engage these)

Protein	Name	Similarity
Q5R1S9	—	1.000	Q5R1S9 →
Q9D0N7	—	0.997	Q9D0N7 →
Q8QFR2	—	0.992	Q8QFR2 →
O42611	—	0.987	O42611 →
Q6ZD63	—	0.983	Q6ZD63 →
Q8BPM2	—	0.981	Q8BPM2 →
Q8C092	—	0.980	Q8C092 →
P70483	—	0.979	P70483 →
Q66JG1	—	0.978	Q66JG1 →
TAF5	Transcription initiation factor TFIID subunit 5	0.978	landscape →
Q9JJ66	—	0.978	Q9JJ66 →
Q9NVU0	—	0.978	Q9NVU0 →
Q921C3	—	0.978	Q921C3 →
O00423	—	0.977	O00423 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.977	landscape →
P58742	—	0.977	P58742 →
Q9SXY1	—	0.977	Q9SXY1 →
Q99JP0	—	0.977	Q99JP0 →
Q15061	—	0.977	Q15061 →
Q5I0B9	—	0.977	Q5I0B9 →
Q68EI0	—	0.976	Q68EI0 →
Q8BMI3	—	0.976	Q8BMI3 →
A2AHJ4	—	0.976	A2AHJ4 →
Q641K1	—	0.976	Q641K1 →
Q5RAC9	—	0.976	Q5RAC9 →
Q9CZT4	—	0.976	Q9CZT4 →
PLAA	Phospholipase A-2-activating protein	0.976	landscape →
Q8N5D0	—	0.976	Q8N5D0 →
Q8VDD9	—	0.976	Q8VDD9 →
Q9R1A8	—	0.975	Q9R1A8 →